Crystal Watson

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation

Global Burden of Stroke

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

The ClusPro web server for protein–protein docking

Generation and Characterization of Small Single Domain Antibodies Inhibiting Human Tumor Necrosis Factor Receptor 1

Funding a Smoking Cessation Program for Crohn’s Disease: An Economic Evaluation

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

Hidradenitis suppurativa

TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants – past, present and future

The global burden of IBD: from 2015 to 2025

epic3: National Evidence-Based Guidelines for Preventing Healthcare-Associated Infections in NHS Hospitals in England

Psychosocial Interventions and Immune System Function

Belonging: a review of conceptual issues, an integrative framework, and directions for future research

Stroke Risk Prediction with Machine Learning Techniques

CAR T cell immunotherapy for human cancer

Healthcare workers' knowledge of inoculation injuries and glove use

Glove usage and reporting of needlestick injuries by junior hospital medical staff.

Cost per Treated Patient for Etanercept, Adalimumab, and Infliximab Across Adult Indications: a Claims Analysis

Short- and longer-term health-care resource utilization and costs associated with acute ischemic stroke

Treatment Patterns in the First Year After Initiating Tumor Necrosis Factor Blockers in Real-World Settings

Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States

Costs of Tumor Necrosis Factor Blockers Per Treated Patient Using Real-World Drug Data in a Managed Care Population